| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1003351624 |
| P356 | DOI | 10.1007/S00240-014-0698-4 |
| P698 | PubMed publication ID | 25086904 |
| P50 | author | Hans-Göran Tiselius | Q67189766 |
| P2860 | cites work | Herbal antioxidant in clinical practice: a review | Q26994202 |
| NADPH oxidase as a therapeutic target for oxalate induced injury in kidneys | Q27014373 | ||
| Vitamin E attenuates crystal formation in rat kidneys: roles of renal tubular cell death and crystallization inhibitors | Q28564916 | ||
| Three pathways for human kidney stone formation | Q28740580 | ||
| Physiopathology and etiology of stone formation in the kidney and the urinary tract | Q33731481 | ||
| Course of calcium stone disease without treatment. What can we expect? | Q33865108 | ||
| Epidemiology and medical management of stone disease | Q34192181 | ||
| Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease | Q34304464 | ||
| Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline | Q34336412 | ||
| Calcium oxalate stone disease: role of lipid peroxidation and antioxidants | Q34593332 | ||
| Prevention of shockwave induced functional and morphological alterations: an overview | Q34784969 | ||
| Medical evaluation of nephrolithiasis | Q35021726 | ||
| Modulators of urinary stone formation | Q35672755 | ||
| A guide to renal stone disease | Q36027205 | ||
| Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline | Q36325704 | ||
| Effects of furosemide on renal calcium handling | Q80672592 | ||
| Role of renal epithelial cells in the initiation of calcium oxalate stones | Q80895355 | ||
| A proposed method for approximate estimates of the ion-activity products of calcium oxalate and calcium phosphate in spot-urine samples or in urine samples collected during less well defined periods of time | Q86414436 | ||
| Urine dipstick analysis for identification of runners susceptible to acute kidney injury following an ultramarathon | Q87409554 | ||
| Is prevention of stone recurrence financially worthwhile? | Q36386115 | ||
| Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis | Q36449199 | ||
| The assessment of 24 24-h urine volume by measurement of urine specific gravity with dipstick in adults with nephrolithiasis | Q37047425 | ||
| Kidney stones: an update on current pharmacological management and future directions | Q37169623 | ||
| Intra-tubular deposits, urine and stone composition are divergent in patients with ileostomy | Q37191601 | ||
| Role of proximal tubule in the hypocalciuric response to thiazide of patients with idiopathic hypercalciuria | Q37476617 | ||
| Protein inhibitors of crystallization. | Q37720519 | ||
| A hypothesis of calcium stone formation: an interpretation of stone research during the past decades | Q37829930 | ||
| Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations | Q38047594 | ||
| The role of calcium phosphate in the development of Randall's plaques | Q38130426 | ||
| A meta-analysis of coffee intake and risk of urolithiasis | Q38185882 | ||
| Citrate and vitamin E blunt the shock wave-induced free radical surge in an in vitro cell culture model | Q40345914 | ||
| Evidence of calcium phosphate supersaturation in the loop of Henle | Q40943169 | ||
| Calcium phosphate: an important crystal phase in patients with recurrent calcium stone formation? | Q41081025 | ||
| Vitamin C: the nontoxic, nonrate-limited, antioxidant free radical scavenger | Q41506998 | ||
| Ascorbic acid supplements and kidney stone incidence among men: a prospective study | Q43599458 | ||
| Hydroxyapatite induction and secondary aggregation of calcium oxalate, two important processes in calcium stone formation | Q43877482 | ||
| Presence of lipids in urine, crystals and stones: implications for the formation of kidney stones | Q44213008 | ||
| Validation of Randall's plaque theory using unenhanced abdominal computed tomography | Q44349561 | ||
| Aspects on Estimation of the Risk of Calcium Oxalate Crystallization in Urine | Q44519960 | ||
| Determination of the calcium oxalate crystallization risk from urine samples: the BONN Risk Index in comparison to other risk formulas | Q44940150 | ||
| Urinary lithogenesis risk tests: comparison of a commercial kit and a laboratory prototype test. | Q45351730 | ||
| Studies on the role of calcium phosphate in the process of calcium oxalate crystal formation. | Q46011036 | ||
| Ureteral stones: SWL treatment | Q46422314 | ||
| Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status | Q46552906 | ||
| Improved cost-effectiveness and efficiency with a slower shockwave delivery rate | Q48398961 | ||
| Stone formation and urine composition in calcium stone formers without medical treatment. | Q50558478 | ||
| Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate. | Q50658717 | ||
| Calcium reabsorption in the distal tubule: regulation by sodium, pH, and flow. | Q51300124 | ||
| Spot urine samples for the metabolic evaluation of urolithiasis patients. | Q51577380 | ||
| Measurement of the risk of calcium oxalate crystallization in urine. | Q54401994 | ||
| Calcium oxalate crystallization properties in urine with different specific electrical conductivities | Q68021274 | ||
| Clinical significance of phosphate in calcium oxalate renal stones | Q68058737 | ||
| Measurement of the risk of calcium phosphate crystallization in urine | Q69045056 | ||
| The composition of four-hour urine samples from patients with calcium oxalate stone disease | Q69465610 | ||
| Inhibitors within the nephron | Q70126491 | ||
| Variations in urine composition during the day in patients with calcium oxalate stone disease | Q70788685 | ||
| Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation | Q72717066 | ||
| Factors influencing the course of calcium oxalate stone disease | Q73071501 | ||
| Some aspects of the intratubular precipitation of calcium salts | Q73131800 | ||
| Estimated levels of supersaturation with calcium phosphate and calcium oxalate in the distal tubule | Q73326742 | ||
| Crystallization in the nephron | Q73393268 | ||
| In vitro crystallisation systems for the study of urinary stone formation | Q73655268 | ||
| P921 | main subject | calcium oxalate | Q412399 |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 47-57 | |
| P577 | publication date | 2014-08-03 | |
| P1433 | published in | Urolithiasis | Q27724667 |
| P1476 | title | Should we modify the principles of risk evaluation and recurrence preventive treatment of patients with calcium oxalate stone disease in view of the etiologic importance of calcium phosphate? | |
| P478 | volume | 43 Suppl 1 |
| Q54945958 | Anti-Transforming Growth Factor β IgG Elicits a Dual Effect on Calcium Oxalate Crystallization and Progressive Nephrocalcinosis-Related Chronic Kidney Disease. |
| Q64962529 | Comparison of the adhesion of calcium oxalate monohydrate to HK-2 cells before and after repair using tea polysaccharides. |
| Q60043943 | Effect of sample time on urinary lithogenic risk indexes in healthy and stone-forming adults and children |
| Q89217016 | Kidney stones |
| Q38650727 | Metabolic risk-evaluation and prevention of recurrence in stone disease: does it make sense? |
| Q39869394 | The influence of maternal and paternal history on stone composition and clinical course of calcium nephrolithiasis in subjects aged between 15 and 25. |
Search more.